亚洲日韩欧美综合-亚洲日韩欧美一区二区在线-亚洲日韩欧美视频-亚洲日韩精品欧美一区二区-国产欧美日韩综合

達卡他韋現貨價格湖北威德利專業生產廠家

 
 
單價 面議對比
詢價 暫無
發貨 湖北武漢市付款后3天內
品牌 威德利
過期 長期有效
更新 2017-12-15 15:51
 

湖北威德利化學科技公司

企業會員第13年
資料未認證
保證金未繳納
詳細說明
達卡他韋現貨價格湖北威德利專業生產廠家

達卡他韋報價原料供應商專業生產廠家現貨報價湖北威德利

達卡他韋1009119-65-6生產廠家現貨價格湖北威德利

達卡他韋原料藥專業生產廠家湖北威德利供應達卡他韋及其中間體

我公司專業生產銷售達卡他韋原料藥,產品遠銷歐美,獲得國內外合作伙伴一致好評聯系湖北威德利獲得達卡他韋最新市場行情,達卡他韋現貨價格信息
18827677254|027-8377 8895|QQ3O96367716

達卡他韋
威德利新開發達卡他韋原料藥
中文名稱 達卡他韋
英文名稱 Daclatasvir
CAS RN 1009119-65-6(1214735-16-6);1009119-64-5
分子式 C40H50N8O6.2(HCl)
分子量 738.88
純度 99.0%
1009119-64-5游離,1009119-65-6
包裝 100克/袋,陰涼干燥

達卡他韋多少錢,達卡他韋價格,達卡他韋哪里有,達卡他韋哪家工廠生產,阿加曲班供應商,達卡他韋現貨,達卡他韋報價,達卡他韋含量,湖北威德利達卡他韋價格,歡迎來電咨詢18827677254|027-8377 8895|QQ3O96367716
舉報收藏 0評論 0
更多>本企業其它產品
埃博霉素B原料廠家現貨威德利品牌 度魯特韋1051375-16-6原料藥現貨價格市場行情咨詢 阿維菌素原料廠家現貨威德利品牌 艾地苯醌原料廠家現貨威德利品牌 丙酸氯倍他索原料藥廠家現貨威德利品牌 度魯特韋1051375-16-6原料藥現貨價格市場行情咨詢 恩格列凈原料藥威得利市場行情咨詢
 
主站蜘蛛池模板: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |